The tablet formulation of zanubrutinib (Brukinsa; BeOne) has become approved for all five indications throughout many hematological cancers.The modified stem cells provide the human body with myeloid (immune) cells that generate the ARSA enzyme, which allows break down the dangerous Make-up of sulfatides and may halt the progression of MLD.  Ahead